The cleavage and inactivation of plasminogen activator inhibitor type 1 and α2-antiplasmin by reptilase, a thrombin-like venom enzyme

Blood Coagulation and Fibrinolysis

Volumn 11, Issue 2, 2000, Pages 145-153

  Urano, T ^a   Ihara, H ^a   Takada, Y ^b   Fujie, M ^c   Takada, Akikazu ^a  

^a HAMAMATSU UNIVERSITY   (Japan)

^b Department of Pathophysiology ^*  (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

A2 antiplasmin; Batroxobin; Defibrination; Fibrinolysis; Plasminogen activator inhibitor type 1

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANCROD; ANTIFIBRINOLYTIC AGENT; BATROXOBIN; CHROMOGENIC SUBSTRATE; FIBRIN MONOMER; FIBRINOGEN; FIBRINOPEPTIDE A; HEPARIN; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; VENOM;

ARTICLE; CARBOXY TERMINAL SEQUENCE; DRUG EFFECT; DRUG MECHANISM; EUGLOBULIN LYSIS TEST; FIBRINOGEN BLOOD LEVEL; FIBRINOGENOLYSIS; FIBRINOLYSIS; HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 0034005092     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200011020-00005     Document Type: Article

References (31)

1. 1. Pirkle H, Stocker K. Thrombin-like enzymes from snake venoms: an inventory. For the Subcommittee on Nomenclature of Exogenous Hemostatic Factors of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1991; 65: 444-450.
2. 2. Kwaan HC. Use of defibrinating agents ancrod and reptilase in the treatment of thromboembolism. Thromb Diath Haemorrh Suppl 1973; 56: 239-251.
3. 3. Markland FS. Snake venoms and the hemostatic system. Toxicon 1998; 36: 1749-1800.
4. 4. Marsh N. Fibrinolysis. New York: John Willey & Sons, 1981.
5. 5. Collen D, Verstraete M. Plasmin-antiplasmin complex formation during defibrase infusion in man. Thromb Res 1977; 11: 417-420.
6. 6. Prentice CR, Hampton KK, Grant PJ, Nelson SR, Nieuwenhuizen W, Gaffney PJ. The fibrinolytic response to ancrod therapy: characterization of fibrinogen and fibrin degradation products. Br J Haematol 1993; 83: 276-281.
7. 7. Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb 1989; 9: 87-115.
8. 8. Urano T, Sumiyoshi K, Pietraszek MH, Takada Y, Takada A. PAI-1 plays an important role in the expression of t-PA activity in the euglobulin clot lysis by controlling the concentration of free t-PA. Thromb Haemost 1991; 66: 474-478.
9. 9. Carrell RW, Evans DL, Stein PE. Mobile reactive centre of serpins and the control of thrombosis. Nature 1991; 353: 576-578.
10. 10. Ehrlich HJ, Gebbink RK, Preissner KT, Keijer J, Esmon NL, Mertens K, et al. Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix. J Cell Biol 1991; 115: 1773-1181.
11. 11. Keijer J, Linders M, Wegman JJ, Ehrlich HJ, Mertens K, Pannekoek H. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site. Blood 1991; 78: 1254-1261.
12. 12. Wu K, Urano T, Ihara H, Takada Y, Fujie M, Shikimori M, et al. The cleavage and inactivation of plasminogen activator inhibitor type 1 by neutrophil elastase: the evaluation of its physiologic relevance in fibrinolysis. Blood 1995; 86: 1056-1061.
13. 13. Urano T, Nagai N, Matsuura M, Ihara H, Takada Y, Takada A. Human thrombin and calcium bound factor Xa significantly shorten tPA-induced fibrin clot lysis time via neutralization of plasminogen activator inhibitor type 1 activity. Thromb Haemost 1998; 80: 161-166.
14. 14. Sugiki M, Maruyama M, Yoshida E, Mihara H, Kamiguti AS, Theakston DG. Enhancement of plasma fibrinolysis in vitro by jararhagin, the main haemorrhagic metalloproteinase in Bothrops jararaca venom. Toxicon 1995; 33: 1605-1617.
15. 15. Kress LF, Catanese J, Hirayama T. Analysis of the effects of snake venom proteinases on the activity of human plasma C1 esterase inhibitor, alpha 1-anti-chymotrypsin and alpha 2-antiplasmin. Biochim Biophys Acta 1983; 745: 113-120.
16. 16. Kress LF. Inactivation of human plasma serine proteinase inhibitors (serpins) by limited proteolysis of the reactive site loop with snake venom and bacterial metalloproteinases. J Cell Biochem 1986; 32: 51-58.
17. 17. Lawrence D, Strandberg L, Grundstrom T, Ny T. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells. Eur J Biochem 1989; 186: 523-533.
18. 18. Jameson GW, Roberts DV, Adams RW, Kyle WS, Elmore DT. Determination of the operational molarity of solutions of bovine alpha-chymotrypsin, trypsin, thrombin and factor Xa by spectrofluorimetric titration. Biochem J 1973; 131: 107-117.
19. 19. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
20. 20. Urano T, Strandberg L, Johansson LB, Ny T. A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate. Eur J Biochem 1992; 209: 985-992.
21. 21. Suenson E, Thorsen S. The course and prerequisites of Lys-plasminogen formation during fibrinolysis. Biochemistry 1988; 27: 2435-2443.
22. 22. Urano T, Takada Y, Ihara H, Takada A. Reexamination of the extent of the activation of lys78-plasminogen by tissue plasminogen activator in the presence of polymerized fibrin. Haemostasis 1996; 26: 220-227.
23. 23. Urano T, Sakakibara K, Rydzewski A, Urano S, Takada Y, Takada A. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1. Thromb Haemost 1990; 63: 82-86.
24. 24. Ny T, Sawdey M, Lawrence D, Millan JL, Loskutoff DJ. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci USA 1986; 83: 6776-6780.
25. 25. Holmes WE, Nelles L, Lijnen HR, Collen D. Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor (serpin). J Biol Chem 1987; 262: 1659-1664.
26. 2-terminal form with 12 additional residues of alpha 2-plasmin inhibitor from human plasma and culture media of Hep G2 cells. Biochem Biophys Res Commun 1994; 200: 417-422.
27. 27. Yoshida N, Wada H, Morita K, Hirata H, Matsuda M, Yamazumi K, et al. A new congenital abnormal fibrinogen Ise characterized by the replacement of B beta glycine-15 by cysteine. Blood 1991; 77: 1958-1963.
28. 28. Travis J, Salvesen GS. Human plasma proteinase inhibitors. Ann Rev Biochem 1983; 52: 655-709.
29. 29. Ottonello L, Dapino P, Scirocco M, Dallegri F, Sacchetti C. Proteolytic inactivation of alpha-1-anti-trypsin by human neutrophils: involvement of multiple and interlinked cell responses to phagocytosable targets. Eur J Clin Invest 1994; 24: 42-49.
30. 30. Bell WJ. Defibrinogenating enzymes. Drugs 1997; 3: 18-30.
31. 31. Atkinson RP. Ancrod in the treatment of acute ischaemic stroke. Drugs 1997; 3: 100-108.